US and UK Agree to Zero-Tariff Arrangement on Prescription Drugs.
The UK and US have secured a landmark bilateral deal that will guarantee no import taxes on UK drug products entering the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to boost expenditure on pharmaceuticals through the NHS. This move ensures that import taxes on these vital products will be held at nothing for a period of the next three years.
This development follows previous statements to hike import taxes on patented drug imports, with potential rates mentioned as high as one hundred percent.
"This agreement with the UK reinforces the international landscape for new treatments and brings much-needed balance to transatlantic drug exports," a release declared.
Commercial Significance
Drugs represent one of the UK's biggest export categories to the United States, which is clearly the primary destination for large companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months to the end of the third quarter, the UK sold drugs worth over eleven billion pounds to the US. This value made up a significant portion of all goods exports in that timeframe.
"This guarantee secures jobs, stimulates capital expenditure and facilitates the UK to establish itself as a worldwide center for biotech and pharma," the Business and Trade Secretary stated.
Specific UK Commitments
The pact involves several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a target to increase total health service expenditure on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The sum manufacturers must pay back to the NHS to stay within budget will be restricted at fifteen percent. Last year, refunds exceeded 20%.
Industry Background
The deal comes amid a long-running row between the drug companies and the British authorities over drug pricing and approval rates.
The disagreement were heightened by claims that American patients were paying significantly more for the identical medicines than patients in the Britain and the EU.
In recent months, several large manufacturing plans in the UK have been paused or cancelled, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
The Science Minister stated that the NHS needed to spend more on drugs, noting that its spending on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.